Xia, Yuxing http://orcid.org/0000-0002-8415-8256
Prokop, Stefan
Bell, Brach M.
Gorion, Kimberly-Marie M.
Croft, Cara L. http://orcid.org/0000-0001-7969-5084
Nasif, Lith http://orcid.org/0000-0001-5515-6115
Xu, Guilian
Riffe, Cara J.
Manaois, Alyssa N.
Strang, Kevin H.
Quintin, Stephan S. http://orcid.org/0000-0002-5880-8470
Paterno, Giavanna
Tansey, Malú Gámez http://orcid.org/0000-0002-1719-4708
Borchelt, David R.
Golde, Todd E.
Giasson, Benoit I. http://orcid.org/0000-0003-2992-4234
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (F30AG067673)
Article History
Received: 1 December 2021
Accepted: 14 April 2022
First Online: 12 May 2022
Competing interests
: TEG is a cofounder of Lacerta Therapeutics, Inc. and Andante Biologics Inc., and serves on their scientific advisory boards (SABs). He is on the SAB for Promis Neuroscience, Inc. In the past, he has served, ad hoc, on SABs related to neurodegenerative disease programs for Eli Lilly, Novartis, Bristol Myers Squib, Abbvie, Lundbeck, Biogen, and Pfizer. He has served on the medical and scientific advisory board for the Alzheimer’s Association. He serves as a scientific advisor and participates in grant reviews for BrightFocus Foundation and the American Federation for Aging Research. He is a co-inventor on multiple patents and patent applications relating to AD therapeutics. The remaining authors declare no competing interests.